Skip to Main Content

Try STAT+ TODAY

pharmaceuticals

Most Read

Pharmalot Ed Silverman

STAT Plus: Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients

Pharmalot Ed Silverman

STAT Plus: Pharma wins a key round in a court battle with hospitals over a drug discount program

Pharmalot Ed Silverman

STAT Plus: ‘A classic case’: A legal expert explains why lawsuits challenging abortion pill restrictions may succeed

First Opinion Emil D. Kakkis

STAT Plus: As it turns 40, the Orphan Drug Act for rare diseases needs a refresh

Pharmalot Ed Silverman

STAT Plus: A bellwether for biosimilars: Why the new competition for Humira matters to pharma, payers, and patients

Pharmalot Ed Silverman

STAT Plus: Warren urges the FTC to scrutinize two pharma mergers over “anti-competitive” practices

Health Andrew Joseph

FDA pulls Evusheld authorization as coronavirus evolution quashes another therapy

First Opinion Thomas J. Moore and G. Caleb Alexander

A dangerous loophole for drug ads needs to be closed

All Coverage

Pharmalot Ed Silverman

STAT Plus: Turkish court hands Novartis and Roche a rare win over their efforts to promote an eye treatment

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

advertisement

Health Andrew Joseph

STAT Plus: They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help

Politics John Wilkerson

STAT Plus: Teva quits brand lobby PhRMA, in line to lead generic lobby AAM

First Opinion Cathy Tie

Generics: a missing piece in China’s Covid-19 crisis response

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharma Alex Hogan and Mallory Brangan

STAT Plus: Watch: How do the new obesity drugs work?

Pharmalot Ed Silverman

STAT Plus: Lilly turns to nonprofit, not the FDA, to resolve dispute with Novartis over a prescription drug ad

First Opinion Stacey McKenna

STAT Plus: Making naloxone available over the counter won’t solve the overdose crisis — but it will help

Politics John Wilkerson

STAT Plus: The 4 biggest questions about the FDA’s forthcoming changes to accelerated approvals

Special Report Rosa Furneaux and Laura Margottini — TBIJ

STAT Plus: The drug was meant to save children’s lives. Instead, they’re dying

Pharmalot Ed Silverman

STAT Plus: Doctors’ group complains that 60 Minutes segment on Wegovy was really just an ad

Health Tech Mohana Ravindranath

STAT Plus: Amazon Pharmacy expands with new $5 monthly prescription service

Pharmalot Ed Silverman

STAT Plus: Many pediatric drug study results were never posted to a U.S. government database

Politics Sarah Owermohle

STAT Plus: Health groups like AHA, PhRMA channeled millions into end-of-year legislative debates

Politics Rachel Cohrs

STAT Plus: PhRMA terminates lobbying contract with White House official’s brother

Pharmalot Ed Silverman

STAT Plus: Despite court ruling, FDA will continue with its approach to approving orphan drug exclusivity

Pharmalot Ed Silverman

STAT Plus: FTC wants ‘pharma bro’ Martin Shkreli held in contempt for violating lifelong ban on working in pharma

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

First Opinion Paul Hastings

STAT Plus: Biopharma leaders helped save democracy. Now what?

Health Elaine Chen

STAT Plus: Mix-it-yourself Wegovy? Some are trying risky sources for weight-loss drugs

Pharmalot Ed Silverman

STAT Plus: Major purchasers predict expensive new therapies will keep driving drug price hikes

Pharmalot Ed Silverman

STAT Plus: Large health insurers lowered barriers to fair access to some drugs, analysis finds

First Opinion Daniel Eisenkraft Klein

STAT Plus: Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it

Health Tech Katie Palmer

STAT Plus: Telehealth patients are scrambling for in-person care amid crackdown on online controlled substances